

A/D

581-AD

OT15 Rec'd PCT/PTO 29 JUN 2004

10-07-2004

10/500476

Attny Docket No. X-15476

To the Honorable Commissioner for Patents and



original documents or copy thereof:
receiving party(ies):

1. Name of conveying party(ies):
PLEASE SEE ATTACHED

102854326

Name: ELI LILLY AND COMPANY

Additional name(s) of conveying party(ies)
attached? (X) Yes () No

Internal Address: Patent Division

Street Address: Lilly Corporate Center

City: Indianapolis State: Indiana Zip: 46285

3. Nature of conveyance:

(X) Assignment () Merger
() Security Agreement () Change of Name
() Other
Execution Date: PLEASE SEE ATTACHED

Additional name(s) & address(es) attached?

() Yes () No

6/29/04

4. Application number(s) or patent Number(s):

This document is being filed together with a 35 USC 371 application for PCT/US03/00033 filed 21 January 2003.

A. Patent Application No.(s):

B. Patent No.(s):

Additional Numbers attached () Yes (X) No

5. Name and address of party to whom
correspondence concerning documents
should be mailed:

Kimberly S. Rhoades
Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, IN 46206-6288

6. Total number of applications and
patents involved: (1)

7. Total fee (37 CFR §3.41) \$160.00
(\$40.00 per assignment)

() Enclosed
(X) Authorized to be charged to deposit account (along with
any additional fees or the credit of any overpayment)

8. Deposit account number: 05-0840

07/07/2004 LLANDGRA 00000004 050840 10500476
05 FC:8021 40.00 DA

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Soonhee JANG

Soonhee JANG
Reg. No. 44,802

6/29/2004

Date

Total number of pages including cover sheet, attachments and documents (13)

"Express Mail" mailing label number EL832897419 US

Date of Deposit 29 JUNE 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

QUEEN THOMAS

Printed Name

Queen Thomas

Signature

Mail documents to be recorded with required cover sheet information to:
Commissioner for Patents & Trademarks, Mail Stop Assignments,
P.O. Box 1450, Alexandria, VA 22313-1450

1. Name of conveying party(ies):

1. Ryan Thomas BACKER
2. Ivan COLLADO CANO
3. Oscar DE FRUTOS-GARCIA
4. Christopher William DOECKE
5. Matthew Joseph FISHER
6. Steven Lee KUKLISH
7. Vincent MANCUSO
8. Michael John MARTINELLI
9. Jeffrey Thomas MULLANEY
10. Paul Leslie ORNSTEIN
11. Chaoyu XIE

3. Execution Date:

- February 15, 2002
- January 28, 2002
- March 11, 2002
- February 14, 2002
- February 15, 2002
- February 15, 2002
- January 30, 2002
- February 12, 2002
- February 15, 2002
- February 13, 2002
- February 13, 2002

A S S I G N M E N T

WHEREAS I, Oscar de Frutos Garcia, have made an invention which is the subject of a PROVISIONAL PATENT APPLICATION, titled, MELANOCORTIN RECEPTOR AGONISTS; filed January 23, 2002, as application Serial No. 60/351,200 (hereinafter the "Application"); and

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire my entire right, title, and interest in the Application and in all inventions disclosed in the Application;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, I hereby sell, assign, transfer and set over unto Eli Lilly and Company, its successors and assigns (collectively, "Lilly") my entire right, title, and interest in, the Application and in all inventions disclosed therein; all rights of priority thereto pursuant to the International Convention for the Protection of Industrial Property; any and all present or future patent applications to such inventions that may be filed in the United States or any foreign country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications under the Patent Cooperation Treaty ("PCT"), United States provisional patent applications, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates, copyrights, trademarks, and data package exclusivity rights; and any and all Letters Patent of the United States and of all foreign countries and all related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

IN WITNESS WHEREOF I have executed this assignment on the date indicated below.

Date
March 11th, 2002

Oscar de Frutos Garcia


ASSIGNMENT

WHEREAS I, Ivan Collado Cano, have made an invention which is the subject of a PROVISIONAL PATENT APPLICATION, titled, MELANOCORTIN RECEPTOR AGONISTS, filed January 23, 2002, as application Serial No. 60/351,200 (hereinafter the "Application"); and

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire our entire right, title, and interest in the Application and in all inventions disclosed in the Application;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, we hereby sell, assign, transfer and set over unto Eli Lilly and Company, its successors and assigns (collectively, "Lilly") our entire right, title, and interest in, the Application and in all inventions disclosed therein; all rights of priority thereto pursuant to the International Convention for the Protection of Industrial Property; any and all present or future patent applications to such inventions that may be filed in the United States or any foreign country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications under the Patent Cooperation Treaty ("PCT"), United States provisional patent applications, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates, copyrights, trademarks, and data package exclusivity rights; and any and all Letters Patent of the United States and of all foreign countries and all related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by us had this Assignment and sale to Lilly not been made.

For ourselves and for our heirs, successors and legal representatives, we covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For ourselves and for our heirs, successors and legal representatives, we further covenant and agree with Lilly that upon request we and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to us or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and

complete legal and equitable title to all such Letters Patent and related intellectual property.

IN WITNESS WHEREOF we have executed this assignment on the date indicated below.

01-28-2002

Date



Ivan Collado Cano

ASSIGNMENT

WHEREAS I, Vincent Mancuso, have made an invention which is the subject of a **PROVISIONAL PATENT APPLICATION**, titled, **MELANOCORTIN RECEPTOR AGONISTS**, filed January 23, 2002, as application Serial No. 60/351,200 (hereinafter the "Application"); and

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire our entire right, title, and interest in the Application and in all inventions disclosed in the Application;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, we hereby sell, assign, transfer and set over unto Eli Lilly and Company, its successors and assigns (collectively, "Lilly") our entire right, title, and interest in, the Application and in all inventions disclosed therein; all rights of priority thereto pursuant to the International Convention for the Protection of Industrial Property; any and all present or future patent applications to such inventions that may be filed in the United States or any foreign country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications under the Patent Cooperation Treaty ("PCT"), United States provisional patent applications, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates, copyrights, trademarks, and data package exclusivity rights; and any and all Letters Patent of the United States and of all foreign countries and all related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by us had this Assignment and sale to Lilly not been made.


For ourselves and for our heirs, successors and legal representatives, we covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For ourselves and for our heirs, successors and legal representatives, we further covenant and agree with Lilly that upon request we and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to us or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and

complete legal and equitable title to all such Letters Patent and related intellectual property.

IN WITNESS WHEREOF we have executed this assignment on the date indicated below.

30/01/02
Date



Vincent Mancuso

A S S I G N M E N T

WHEREAS we, Ryan Thomas Backer; Christopher William Doecke; Matthew Joseph Fisher; Steven Lee Kuklish; Michael John Martinelli; Jeffrey Thomas Mullaney; Paul Leslie Ornstein; and Chaoyu Xie, have made an invention which is the subject of a PROVISIONAL PATENT APPLICATION, titled, **MELANOCORTIN RECEPTOR AGONISTS**, filed January 23, 2002, as application Serial No. 60/351,200 (hereinafter the "Application"); and

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire our entire right, title, and interest in the Application and in all inventions disclosed in the Application;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, we hereby sell, assign, transfer and set over unto Eli Lilly and Company, its successors and assigns (collectively, "Lilly") our entire right, title, and interest in, the Application and in all inventions disclosed therein; all rights of priority thereto pursuant to the International Convention for the Protection of Industrial Property; any and all present or future patent applications to such inventions that may be filed in the United States or any foreign country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications under the Patent Cooperation Treaty ("PCT"), United States provisional patent applications, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates, copyrights, trademarks, and data package exclusivity rights; and any and all Letters Patent of the United States and of all foreign countries and all related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by us had this Assignment and sale to Lilly not been made.

For ourselves and for our heirs, successors and legal representatives, we covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For ourselves and for our heirs, successors and legal representatives, we further covenant and agree with Lilly that upon request we and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to us or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for

Feb. 12, 2002
Date

Michael John Martinelli
Michael John Martinelli

UNITED STATES OF AMERICA

STATE OF INDIANA)
COUNTY OF Marion) ss:

Before me, a Notary Public for Marion County, State of Indiana, personally appeared Michael John Martinelli and acknowledged the execution of the foregoing instrument this 12th day of Feb, 2002.

Michael J. Martinelli
Notary Public

My commission expires:

7-26-06

2-15-2002
Date

Jeffrey Thomas Mullaney
Jeffrey Thomas Mullaney

UNITED STATES OF AMERICA

STATE OF INDIANA)
COUNTY OF MARION) ss:

Before me, a Notary Public for Hendricks County, State of Indiana, personally appeared Jeffrey Thomas Mullaney and acknowledged the execution of the foregoing instrument this 15th day of February, 2002.

Susan L. Buis
Notary Public

My commission expires:

Susan L. Buis
Hendricks County
My Commission Expires
February 11, 2008

